Diabetes Mellitus, Type 2
Conditions
Brief summary
This study is testing the safety and tolerability of subcutaneous semaglutide in participants with type 2 diabetes (T2D) in Chile. Participants will get a once-weekly subcutaneous injection of semaglutide in doses decided by the study doctor's criteria, according to participant's personal needs. The study will last for about 24 weeks. Participants will have 4 clinic visits and 2 phone calls. Participants will have 3 laboratory tests during the study (blood and urine samples).
Interventions
DRUGSemaglutide
Participants will receive semaglutide s.c. injection once weekly in a dose escalation manner for 24 weeks.
Sponsors
Novo Nordisk A/S
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participants diagnosed (clinically) with type 2 diabetes greater than equal to (≥) 90 days prior to the screening visit. * Stable daily dose of Oral Antidiabetic Drug (OAD) and/or insulin treatment for ≥ 60 days prior to the screening visit. * HbA1c 7.5-10% (59-86 millimoles per mole \[mmol/mol\]) (both inclusive) in Visit 1. * Participants in which Ozempic is indicated according to approved local label. * Fundoscopy/Fundus photography record less than equal to (≤) 12 months.
Exclusion criteria
* Known or suspected hypersensitivity to study intervention(s) or related products. * Previous participation in this study. Participation is defined as signed informed consent. * Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method. * Participation in any clinical trial of an approved or non-approved investigational medicinal product within 30 days before the screening visit, except Coronavirus Disease 2019 (COVID-19) related trials (this is allowed). * Treatment with any glucagon-like peptide-1 receptor agonists (GLP-1 RA) medication prior to the screening visit. * Any disorder which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol. * Family or personal history of Multiple Endocrine Neoplasia Type 2 or Medullary Thyroid Carcinoma. * History of pancreatitis (acute or chronic). * Renal impairment defined as estimated glomerular filtration rate (eGFR) below 30 milliliters/minute (mL/min)/1.73 meter square (m\^2) as per MDRD-4 (Modification of Diet in Renal Disease). * Myocardial infarction, stroke or hospitalisation for unstable angina or transient ischaemic attack within the past 180 days prior to the day of screening. * Participants presently classified as being in New York Heart Association (NYHA) Class IV heart failure. * Planned coronary, carotid or peripheral artery revascularisation known on the day of screening. * Participants with alanine aminotransferase (ALT) \> 2.5 x upper normal limit (UNL). * Use of systemic immunosuppressive treatment within 90 days prior to screening. * Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 90 days before the day of screening. An exception is short-term insulin treatment for acute illness for a total of ≤ 14 days. * Known hypoglycaemic unawareness and/or recurrent severe hypoglycaemic episodes as judged by the investigator. * Proliferative retinopathy or maculopathy requiring acute treatment. Verified by fundus photography or dilated fundoscopy performed within 12 months prior to screening. * History or presence of malignant neoplasms within the last 5 years (except basal and squamous cell skin cancer and carcinoma in situ).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Adverse Events (AEs) | From baseline (Day 1) up to 24 weeks | Number of adverse events from baseline (Day 1) to week 24 is presented. An adverse event is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period ends at the first date of any of the following: follow-up visit, premature discontinuation follow-up visit, last date on study product + 42 days for safety and +7 days for efficacy, end-date for the 'in-trial' observation period. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Participants Achieving HbA1c Less Than (<) 7.0 Percentage (%) [Yes/No] | From baseline (week 1) to week 24 | Participants achieving HbA1c less than 7.0% (Yes/No) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit. |
| Change in Fasting Plasma Glucose (FPG) [Milligrams Per Decilitre (mg/dL)] | Baseline (week 1), week 24 | Change in fasting plasma glucose (FPG) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit. |
| Change in Body Weight (Kilogram [Kg]) | Baseline (week 1), week 24 | Change in body weight from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit. |
| Change in Waist Circumference [Centimeter (cm)] | Baseline (week 1), week 24 | Change in waist circumference from baseline (week 1) to week 24 is presented. Waist circumference is defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit. |
| Participants Achieving Greater Than or Equal (≥) 5% Weight Reduction (Yes/No) | From baseline (week 1) to week 24 | Participants achieving greater than or equal (≥) 5% weight reduction (Yes/No) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit. |
| Participants Achieving Greater Than or Equal (≥) 10% Weight Reduction (Yes/No) | From baseline (week 1) to week 24 | Participants achieving greater than or equal (≥) 10% weight reduction (Yes/No) from baseline (week 1) to week is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit. |
| Change in Total Cholesterol (mg/dL) | Baseline (week 1), week 24 | Change in total cholesterol (mg/dL) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit. |
| Change in Low Density Lipoprotein (LDL) Cholesterol (mg/dL) | Baseline (week 1), week 24 | Change in low density lipoprotein (LDL) cholesterol (mg/dL) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit. |
| Change in High Density Lipoprotein (HDL) Cholesterol (mg/dL) | Baseline (week 1), week 24 | Change in high density lipoprotein (HDL) cholesterol (mg/dL) cholesterol from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit. |
| Change in Triglycerides (mg/dL) | Baseline (week 1), week 24 | Change in triglycerides (mg/dL) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit. |
| Change in Glycosylated Haemoglobin (HbA1c) | Baseline (week 1), week 24 | Change in glycosylated haemoglobin (HbA1c) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit. |
| Change in Urine Albumin-Creatinine Ratio (UACR) [Milligram Per Gram (mg/g)] | Baseline (week 1), week 24 | Change in Urine Albumin-Creatinine Ratio (UACR) \[milligram per gram (mg/g)\] from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit. |
| Participants Discontinued Due to Adverse Events (Treatment Discontinuation) | From baseline (week 1) to week 24 | Participants discontinued due to adverse events (treatment discontinuation) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period ends at the first date of any of the following: follow-up visit, premature discontinuation follow-up visit, last date on study product + 42 days for safety and +7 days for efficacy, end-date for the 'in-trial' observation period. |
| Number of Severe Hypoglycaemic Episodes | From baseline (week 1) to week 24 | Number of severe hypoglycaemic episodes from baseline (week 1) to week 24 is presented. Hypoglycaemic episodes were classified as severe if there was no specific glucose threshold but were associated with severe cognitive impairment requiring external assistance for recovery. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), follow-up visit, premature discontinuation follow-up visit. |
| Number of Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes | From baseline (week 1) to week 24 | Number of severe or blood glucose confirmed symptomatic hypoglycaemic episodes from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), follow-up visit, premature discontinuation follow-up visit. |
| Number of Serious Adverse Events (SAEs) | From baseline (week 1) to week 24 | Number of serious adverse events (SAEs) from baseline (week 1) to week 24 is presented. An SAE is any untoward medical occurrence that fulfils at least one of the following criteria: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; important medical event. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period ends at the first date of any of the following: follow-up visit, premature discontinuation follow-up visit, last date on study product + 42 days for safety and +7 days for efficacy, end-date for the 'in-trial' observation period. |
| Number of Adverse Reactions (ARs) | From baseline (week 1) to week 24 | Number of adverse reactions (ARs) from baseline (week 1) to week 24 is presented. Adverse reaction is an undesired effect of a drug or other type of treatment that can range from mild to severe and can be life-threatening. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period ends at the first date of any of the following: follow-up visit, premature discontinuation follow-up visit, last date on study product + 42 days for safety and +7 days for efficacy, end-date for the 'in-trial' observation period. |
| Number of Serious Adverse Reactions (SARs) | From baseline (week 1) to week 24 | Number of serious adverse reactions (SARs) from baseline (week 1) to week 24 is presented. Serious adverse reaction is an adverse reaction that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period ends at the first date of any of the following: follow-up visit, premature discontinuation follow-up visit, last date on study product + 42 days for safety and +7 days for efficacy, end-date for the 'in-trial' observation period. |
| Number of Suspected Unexpected Serious Adverse Reactions (SUSARs) Per Participant | From baseline (week 1) to week 24 | Number of suspected unexpected serious adverse reactions (SUSARs) per participant from baseline (week 1) to week 24 is presented. SUSAR is a serious adverse event which is unexpected and regarded as possibly or probably related to the trial product. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period ends at the first date of any of the following: follow-up visit, premature discontinuation follow-up visit, last date on study product + 42 days for safety and +7 days for efficacy, end-date for the 'in-trial' observation period. |
| Change From Baseline in Heart Rate (Pulse) After 24 Weeks of Treatment | Baseline (week 1), week 24 | Change from baseline in heart rate (pulse) after 24 weeks of treatment is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit. |
| Change in Estimated Glomerular Filtration Rate (eGFR) [Millilitre Per Minute (mL/Min) Per 1.73 Square Meter (m^2)] | Baseline (week 1), week 24 | Change in estimated glomerular filtration rate (eGFR) \[millilitre per minute (mL/min) per 1.73 square meter (m\^2)\] from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit. |
Countries
Chile
Participant flow
Recruitment details
The trial was conducted at 3 sites in Chile.
Participants by arm
| Arm | Count |
|---|---|
| Semaglutide Participants received subcutaneous (s.c.) injection of Semaglutide once-weekly in a dose escalation manner for 24 weeks: 0.25 milligrams \[mg\], (weeks 1 to 4), 0.5 mg (weeks 5 to 12) and 0.5 mg or 1.0 mg (weeks 13 to 24). | 104 |
| Total | 104 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 4 |
| Overall Study | Lost to Follow-up | 1 |
| Overall Study | Participant moved to another city and will not come back to Santiago | 1 |
| Overall Study | Participant no longer wants to participate in study, has other priorities | 1 |
| Overall Study | Withdrawal by Subject | 4 |
Baseline characteristics
| Characteristic | Semaglutide |
|---|---|
| Age, Continuous | 58.3 Years STANDARD_DEVIATION 9.3 |
| Race/Ethnicity, Customized Black | 0 Participants |
| Race/Ethnicity, Customized Indigenous | 3 Participants |
| Race/Ethnicity, Customized No specific ethnicity | 60 Participants |
| Race/Ethnicity, Customized Other | 35 Participants |
| Race/Ethnicity, Customized Unknown | 6 Participants |
| Sex: Female, Male Female | 83 Participants |
| Sex: Female, Male Male | 21 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 104 |
| other Total, other adverse events | 18 / 104 |
| serious Total, serious adverse events | 1 / 104 |
Outcome results
Primary
Number of Adverse Events (AEs)
Number of adverse events from baseline (Day 1) to week 24 is presented. An adverse event is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period ends at the first date of any of the following: follow-up visit, premature discontinuation follow-up visit, last date on study product + 42 days for safety and +7 days for efficacy, end-date for the 'in-trial' observation period.
Time frame: From baseline (Day 1) up to 24 weeks
Population: Full analysis set (FAS) included all participants exposed to the study product.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Semaglutide | Number of Adverse Events (AEs) | 45 Events |
Secondary
Change From Baseline in Heart Rate (Pulse) After 24 Weeks of Treatment
Change from baseline in heart rate (pulse) after 24 weeks of treatment is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.
Time frame: Baseline (week 1), week 24
Population: Full analysis set (FAS) included all participants exposed to the study product. Overall Number of Participants Analysed = participants with available data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Semaglutide | Change From Baseline in Heart Rate (Pulse) After 24 Weeks of Treatment | 2.9 beats per minute (bpm) | Standard Deviation 11.2 |
Secondary
Change in Body Weight (Kilogram [Kg])
Change in body weight from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.
Time frame: Baseline (week 1), week 24
Population: Full analysis set (FAS) included all participants exposed to the study product. Overall Number of Participants Analysed = participants with available data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Semaglutide | Change in Body Weight (Kilogram [Kg]) | -5.3 Kg | Standard Deviation 4.3 |
Secondary
Change in Estimated Glomerular Filtration Rate (eGFR) [Millilitre Per Minute (mL/Min) Per 1.73 Square Meter (m^2)]
Change in estimated glomerular filtration rate (eGFR) \[millilitre per minute (mL/min) per 1.73 square meter (m\^2)\] from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.
Time frame: Baseline (week 1), week 24
Population: Full analysis set (FAS) included all participants exposed to the study product. Overall Number of Participants Analysed = participants with available data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Semaglutide | Change in Estimated Glomerular Filtration Rate (eGFR) [Millilitre Per Minute (mL/Min) Per 1.73 Square Meter (m^2)] | -1.1 mL/min per 1.73 m^2 | Standard Deviation 9.8 |
Secondary
Change in Fasting Plasma Glucose (FPG) [Milligrams Per Decilitre (mg/dL)]
Change in fasting plasma glucose (FPG) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.
Time frame: Baseline (week 1), week 24
Population: Full analysis set (FAS) included all participants exposed to the study product. Overall Number of Participants Analysed = participants with available data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Semaglutide | Change in Fasting Plasma Glucose (FPG) [Milligrams Per Decilitre (mg/dL)] | -26.2 mg/dL | Standard Deviation 61.3 |
Secondary
Change in Glycosylated Haemoglobin (HbA1c)
Change in glycosylated haemoglobin (HbA1c) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.
Time frame: Baseline (week 1), week 24
Population: Full analysis set (FAS) included all participants exposed to the study product. Overall Number of Participants Analysed = participants with available data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Semaglutide | Change in Glycosylated Haemoglobin (HbA1c) | -1.6 Percentage of HbA1c | Standard Deviation 1 |
Secondary
Change in High Density Lipoprotein (HDL) Cholesterol (mg/dL)
Change in high density lipoprotein (HDL) cholesterol (mg/dL) cholesterol from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.
Time frame: Baseline (week 1), week 24
Population: Full analysis set (FAS) included all participants exposed to the study product. Overall Number of Participants Analysed = participants with available data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Semaglutide | Change in High Density Lipoprotein (HDL) Cholesterol (mg/dL) | -1.1 mg/dL | Standard Deviation 5.2 |
Secondary
Change in Low Density Lipoprotein (LDL) Cholesterol (mg/dL)
Change in low density lipoprotein (LDL) cholesterol (mg/dL) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.
Time frame: Baseline (week 1), week 24
Population: Full analysis set (FAS) included all participants exposed to the study product. Overall Number of Participants Analysed = participants with available data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Semaglutide | Change in Low Density Lipoprotein (LDL) Cholesterol (mg/dL) | -12.5 mg/dL | Standard Deviation 26.9 |
Secondary
Change in Total Cholesterol (mg/dL)
Change in total cholesterol (mg/dL) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.
Time frame: Baseline (week 1), week 24
Population: Full analysis set (FAS) included all participants exposed to the study product. Overall Number of Participants Analysed = participants with available data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Semaglutide | Change in Total Cholesterol (mg/dL) | -14.1 mg/dL | Standard Deviation 26 |
Secondary
Change in Triglycerides (mg/dL)
Change in triglycerides (mg/dL) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.
Time frame: Baseline (week 1), week 24
Population: Full analysis set (FAS) included all participants exposed to the study product. Overall Number of Participants Analysed = participants with available data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Semaglutide | Change in Triglycerides (mg/dL) | -13.8 mg/dL | Standard Deviation 105.2 |
Secondary
Change in Urine Albumin-Creatinine Ratio (UACR) [Milligram Per Gram (mg/g)]
Change in Urine Albumin-Creatinine Ratio (UACR) \[milligram per gram (mg/g)\] from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.
Time frame: Baseline (week 1), week 24
Population: Full analysis set (FAS) included all participants exposed to the study product. Overall Number of Participants Analysed = participants with available data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Semaglutide | Change in Urine Albumin-Creatinine Ratio (UACR) [Milligram Per Gram (mg/g)] | -18.0 mg/g | Standard Deviation 410.8 |
Secondary
Change in Waist Circumference [Centimeter (cm)]
Change in waist circumference from baseline (week 1) to week 24 is presented. Waist circumference is defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.
Time frame: Baseline (week 1), week 24
Population: Full analysis set (FAS) included all participants exposed to the study product. Overall Number of Participants Analysed = participants with available data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Semaglutide | Change in Waist Circumference [Centimeter (cm)] | -5.7 cm | Standard Deviation 5.7 |
Secondary
Number of Adverse Reactions (ARs)
Number of adverse reactions (ARs) from baseline (week 1) to week 24 is presented. Adverse reaction is an undesired effect of a drug or other type of treatment that can range from mild to severe and can be life-threatening. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period ends at the first date of any of the following: follow-up visit, premature discontinuation follow-up visit, last date on study product + 42 days for safety and +7 days for efficacy, end-date for the 'in-trial' observation period.
Time frame: From baseline (week 1) to week 24
Population: Full analysis set (FAS) included all participants exposed to the study product.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Semaglutide | Number of Adverse Reactions (ARs) | 39 Events |
Secondary
Number of Serious Adverse Events (SAEs)
Number of serious adverse events (SAEs) from baseline (week 1) to week 24 is presented. An SAE is any untoward medical occurrence that fulfils at least one of the following criteria: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; important medical event. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period ends at the first date of any of the following: follow-up visit, premature discontinuation follow-up visit, last date on study product + 42 days for safety and +7 days for efficacy, end-date for the 'in-trial' observation period.
Time frame: From baseline (week 1) to week 24
Population: Full analysis set (FAS) included all participants exposed to the study product.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Semaglutide | Number of Serious Adverse Events (SAEs) | 1 Events |
Secondary
Number of Serious Adverse Reactions (SARs)
Number of serious adverse reactions (SARs) from baseline (week 1) to week 24 is presented. Serious adverse reaction is an adverse reaction that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period ends at the first date of any of the following: follow-up visit, premature discontinuation follow-up visit, last date on study product + 42 days for safety and +7 days for efficacy, end-date for the 'in-trial' observation period.
Time frame: From baseline (week 1) to week 24
Population: Full analysis set (FAS) included all participants exposed to the study product.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Semaglutide | Number of Serious Adverse Reactions (SARs) | 0 Events |
Secondary
Number of Severe Hypoglycaemic Episodes
Number of severe hypoglycaemic episodes from baseline (week 1) to week 24 is presented. Hypoglycaemic episodes were classified as severe if there was no specific glucose threshold but were associated with severe cognitive impairment requiring external assistance for recovery. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), follow-up visit, premature discontinuation follow-up visit.
Time frame: From baseline (week 1) to week 24
Population: Full analysis set (FAS) included all participants exposed to the study product.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Semaglutide | Number of Severe Hypoglycaemic Episodes | 0 Episodes |
Secondary
Number of Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes
Number of severe or blood glucose confirmed symptomatic hypoglycaemic episodes from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), follow-up visit, premature discontinuation follow-up visit.
Time frame: From baseline (week 1) to week 24
Population: Full analysis set (FAS) included all participants exposed to the study product.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Semaglutide | Number of Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes | Severe | 0 Episodes |
| Semaglutide | Number of Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes | Symptomatic | 2 Episodes |
Secondary
Number of Suspected Unexpected Serious Adverse Reactions (SUSARs) Per Participant
Number of suspected unexpected serious adverse reactions (SUSARs) per participant from baseline (week 1) to week 24 is presented. SUSAR is a serious adverse event which is unexpected and regarded as possibly or probably related to the trial product. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period ends at the first date of any of the following: follow-up visit, premature discontinuation follow-up visit, last date on study product + 42 days for safety and +7 days for efficacy, end-date for the 'in-trial' observation period.
Time frame: From baseline (week 1) to week 24
Population: Full analysis set (FAS) included all participants exposed to the study product.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Semaglutide | Number of Suspected Unexpected Serious Adverse Reactions (SUSARs) Per Participant | 0 Events |
Secondary
Participants Achieving Greater Than or Equal (≥) 10% Weight Reduction (Yes/No)
Participants achieving greater than or equal (≥) 10% weight reduction (Yes/No) from baseline (week 1) to week is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.
Time frame: From baseline (week 1) to week 24
Population: Full analysis set (FAS) included all participants exposed to the study product. Overall Number of Participants Analysed = participants with available data.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Semaglutide | Participants Achieving Greater Than or Equal (≥) 10% Weight Reduction (Yes/No) | Yes | 17 Participants |
| Semaglutide | Participants Achieving Greater Than or Equal (≥) 10% Weight Reduction (Yes/No) | No | 75 Participants |
Secondary
Participants Achieving Greater Than or Equal (≥) 5% Weight Reduction (Yes/No)
Participants achieving greater than or equal (≥) 5% weight reduction (Yes/No) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.
Time frame: From baseline (week 1) to week 24
Population: Full analysis set (FAS) included all participants exposed to the study product. Overall Number of Participants Analysed = participants with available data.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Semaglutide | Participants Achieving Greater Than or Equal (≥) 5% Weight Reduction (Yes/No) | Yes | 56 Participants |
| Semaglutide | Participants Achieving Greater Than or Equal (≥) 5% Weight Reduction (Yes/No) | No | 36 Participants |
Secondary
Participants Achieving HbA1c Less Than (<) 7.0 Percentage (%) [Yes/No]
Participants achieving HbA1c less than 7.0% (Yes/No) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.
Time frame: From baseline (week 1) to week 24
Population: Full analysis set (FAS) included all participants exposed to the study product. Overall Number of Participants Analysed = participants with available data.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Semaglutide | Participants Achieving HbA1c Less Than (<) 7.0 Percentage (%) [Yes/No] | Yes | 52 Participants |
| Semaglutide | Participants Achieving HbA1c Less Than (<) 7.0 Percentage (%) [Yes/No] | No | 40 Participants |
Secondary
Participants Discontinued Due to Adverse Events (Treatment Discontinuation)
Participants discontinued due to adverse events (treatment discontinuation) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period ends at the first date of any of the following: follow-up visit, premature discontinuation follow-up visit, last date on study product + 42 days for safety and +7 days for efficacy, end-date for the 'in-trial' observation period.
Time frame: From baseline (week 1) to week 24
Population: Full analysis set (FAS) included all participants exposed to the study product.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Semaglutide | Participants Discontinued Due to Adverse Events (Treatment Discontinuation) | 4 Participants |